Aldeyra Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview
28/07/2025 22:26
Aldeyra Therapeutics Inc ALDX.OQ ALDX.O is expected to show no change in quarterly revenue when it reports results on July 30 (estimated) for the period ending June 30 2025 LSEG's mean analyst estimate for Aldeyra Therapeutics Inc is for a loss of 24 cents per share. The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Aldeyra Therapeutics Inc is $9.50, about 44% above its last closing price of $5.32 Previous quarterly performance (using preferred earnings measure in US dollars).
| QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
| Mar. 31 2025 | -0.30 | -0.28 | -0.17 | Beat | 39.3 |
| Dec. 31 2025 | -0.26 | -0.23 | -0.27 | Missed | -19.9 |
| Sep. 30 2024 | -0.26 | -0.25 | -0.25 | Met | -1.2 |
| Jun. 30 2024 | -0.14 | -0.14 | -0.28 | Missed | -97.5 |
| Mar. 31 2024 | -0.10 | -0.11 | -0.14 | Missed | -26.5 |
| Dec. 31 2023 | -0.05 | -0.14 | -0.08 | Beat | 43 |
| Sep. 30 2023 | -0.22 | -0.24 | -0.14 | Beat | 41.3 |
| Jun. 30 2023 | -0.31 | -0.31 | -0.15 | Beat | 51.8 |
Recent news on Aldeyra Therapeutics
See all newsBrief: Aldeyra Therapeutics Pays Off $15 Million Outstanding Borrowings, Terminates Hercules Credit Facility - SEC Filing
U.S. STOCKS ON THE MOVE -Steel Dynamics, Aldeyra, Cencora
U.S. STOCKS ON THE MOVE-Qualcomm, Canadian Solar, Draftkings
Aldeyra tumbles to record low after FDA declines to approve experimental dry eye drug
Aldeyra plunges after FDA declines to approve experimental dry eye drug